United States CAR-T Cell Therapy Market Size 2028: Projected Growth and Opportunities | Techsci Research

TechSci Research's report titled " United States CAR-T Cell Therapy Market - By Region, Forecast and Opportunities, 2018-2028" predicts a significant growth of the United States CAR-T Cell Therapy Market during the forecast period of 2018-2028 with an impressive CAGR. The growth of the market is attributed to the rise in cancer prevalence, increased awareness among the key market players, and recent developments.

Healthcare researchers have developed an advanced form of cancer treatment called Chimeric Antigen Receptor (CAR) T cell therapy, which involves changing T-cells in the lab and then infusing them into the body of the cancer patient to destroy cancer cells. CAR T-cell therapy enhances the immune response, especially T-cells, against cancerous cells.

The United States CAR-T Cell Therapy Market is being driven by the increase in therapy's adoption and utilization, offering personalized therapy with potentially curative outcomes for cancer patients. However, one of the primary restraining factors is the limited availability of CAR-T therapy, which is a relatively new treatment option. Additionally, the manufacturing process for CAR-T therapy is complex and time-consuming, limiting the number of patients who can receive the treatment. The limited availability of CAR-T therapy makes it difficult for patients, especially those living in rural or remote areas with limited access to healthcare, to access the treatment.

Browse over 30 market data Figures spread through 70 Pages and an in-depth TOC on "United States CAR-T Cell Therapy Market"- https://www.techsciresearch.com/report/united-states-car-t-cell-therapy-market/14917.html

The market for the United States CAR-T Cell Therapy can be segmented by product type, tumor type, indication, treatment type, targeted antigen, end-user, and region. The Yescarta (Axicabtagene Ciloleucel) segment is expected to show impressive growth in the forecast period due to the increase in the adoption of Yescarta (Axicabtagene Ciloleucel) medicine for the treatment of relapsed or refractory large B-cell lymphoma and relapsed or refractory follicular lymphoma.

The Acute Lymphoblastic Leukemia (ALL) segment is expected to show an impressive growth in the forecast period due to the increase in awareness of CAR T-cell therapeutics for the treatment of acute lymphoblastic leukemia and the expected launch of these drugs for the treatment of acute lymphoblastic leukemia regarding testing of blood T-cell cancer.

Based on the end-user, the market can be classified into Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others. The Hospitals segment is expected to show impressive growth in the forecast period due to well-equipped and established operation theatres and an increase in patient admission.

Major companies operating in United States CAR-T Cell Therapy Market include:

• Gilead Sciences, Inc (US)
• Novartis United States
• AbbVie Inc.
• Myriad Genetics
• NeoGenomics Laboratories
• Intellia Therapeutics (US)
• Agilent Technologies, Inc. (US)
• Abcam plc.
• Bio-Techne. (ExoDx)
• Sangamo Therapeutics, Inc. (US)

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“United States CAR-T Cell Therapy Market is expected to witness significant growth during the forecast period on account of rising awareness for different therapies. An increase in number of cancer cases further supports the demand for CAR-T Cell Therapy Market in United States. Additionally, increase in emergence of players developing new therapies and treatment is expected to create lucrative opportunities for the market growth in the next few years” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based global management consulting firm.

“United States CAR-T Cell Therapy Market, By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment Type (Single Treatment, Combination Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, Competition Forecast & Opportunities, 2028”, has evaluated the future growth potential of United States CAR-T Cell Therapy Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States CAR-T Cell Therapy Market.

Download Free Sample Report- https://www.techsciresearch.com/sample-report.aspx?cid=14917

Related Reports:

Egypt contact lenses market

Australia blood bags market

Egypt cancer diagnostic market

United states direct to consumer genetic testing market

About TechSci Research:

TechSci Research is a research-based management consulting firm providing market research and advisory solutions to its customers worldwide, spanning a range of industries. TechSci Research’s core values are value, integrity and insight. Led by a team of dynamic industry experts, TechSci Research provides its customers with high value market research and advisory services that helps them identify new market opportunities, growth engines and innovative ways to capture the market share. As a result, TechSci’s client leads rather than follow market trends. Not bound by legacy, TechSci’s cutting-edge research model leverages its decades of research knowledge and an increased use of technology as engines of innovation to deliver unique research value. Provided as an alternative to traditional market research, TechSci Research reports do not just deliver data and knowledge rather highlights the insights in a more usable and interactive format for its clients.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Web: https://www.techsciresearch.com